Article

On whether therapeutic plasma exchange is an effective cure against severe/critical COVID-19 pneumonia

2021-04-20

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> There is a risk of novel mutations of SARS-CoV-2 that may render COVID-19 resistant to most of the therapies, including antiviral drugs. The evidence around the application of therapeutic plasma exchange (TPE) for the management of critically ill COVID-19 patients is still provisional and further investigations are needed to confirm its eventual beneficial effects. <h4>Methods...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 42eacc16-02a1-5aac-83d1-631b30c0ce2e
DOI: 10.1101/2021.04.19.21255657

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

On whether therapeutic plasma exchange is an effective cure against severe/critical COVID-19 pneumoniaDOI 10.1101/2021.04.19.21255657Read

On Whether Therapeutic Plasma Exchange is Effective Against Severe/Critical COVID-19 PneumoniaSemantic proximity Read

Azvudine Reduce the In-Hospital Mortality of Patients with COVID-19 PneumoniaSemantic proximity Read

COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized trialSemantic proximity Read

Clinical characteristics and laboratory biomarkers changes in COVID-19 patients requiring or not intensive or sub-intensive care: a comparative studySemantic proximity Read

HYDROXYCHLOROQUINE FOR THE TREATMENT OF SEVERE RESPIRATORY INFECTION BY COVID-19: A RANDOMIZED CONTROLLED TRIALSemantic proximity Read

Challenges in the Clinical Management of SARS-CoV2-Infected Patients with Haematological MalignanciesSemantic proximity Read

The Saudi Critical Care Society Practice Guidelines on the Management of COVID-19 in the ICU: Therapy SectionSemantic proximity Read

A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc and/or Favipiravir Vs Currently Used Therapy in Severe COVID-19 Adults. (COMVIVIR, clinicaltrials.gov NCT04475991)Semantic proximity Read

Efficacy and safety of convalescent plasma therapy for severe COVID-19 patients：case series study and literature reviewSemantic proximity Read

A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc and/or Favipiravir vs Currently Used Therapy in Severe COVID-19 Adults. “COMVIVIR” Trial.Semantic proximity Read

Effect of Intravenous N-acetylcysteine on Prevention of Mechanical Ventilation and Mortality among COVID-19 Patients: A Meta-AnalysisSemantic proximity Read

Timing of convalescent plasma administration and 28-day mortality for COVID-19 pneumoniaSemantic proximity Read